RESULT_COUNT: 218,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
BPMC,BPMC:UW,BBG008D08M37,See what the IHS Markit Score report has to say about Blueprint Medicines Corp.,2017-10-17 12:07:06 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120706770.html?.tsrc=rss,"Short interest is low for BPMC with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last month, ETFs holding BPMC are favorable, with net inflows of $3.14 billion."
BPMC,BPMC:UW,BBG008D08M37,"Commit To Purchase Blueprint Medicines Corp At $50, Earn 15.4% Annualized Using Options",2017-10-13 17:12:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AohHdsJglP4/commit-to-purchase-blueprint-medicines-corp-at-50-earn-154-annualized-using-options-cm859527,Investors eyeing a purchase of Blueprint Medicines Corp Symbol BPMC shares but tentative about paying the going market price of 62 88 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
BPMC,BPMC:UW,BBG008D08M37,BPMC Crosses Above Average Analyst Target,2017-10-11 15:13:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ath1fq-6Vrg/bpmc-crosses-above-average-analyst-target-cm858095,In recent trading shares of Blueprint Medicines Corp Symbol BPMC have crossed above the average analyst 12 month target price of 67 17 changing hands for 67 66 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations",2017-10-10 20:01:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-announces-appointment-christopher-200100683.html?.tsrc=rss,"CAMBRIDGE, Mass., Oct. 10, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations.  Dr. Murray will join the executive management team and be responsible for technical development, manufacturing and supply chain operations.  Chris has more than two decades of strategic and operational experience in pharmaceutical sciences, and he has successfully led manufacturing operations for multiple product candidates through development, regulatory review and commercial launch,"" said Jeff Albers, Chief Executive Officer of Blueprint Medicines."
BPMC,BPMC:UW,BBG008D08M37,See what the IHS Markit Score report has to say about Blueprint Medicines Corp.,2017-10-09 12:02:51 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120251857.html?.tsrc=rss,"Short interest is low for BPMC with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last month, ETFs holding BPMC are favorable, with net inflows of $2.66 billion."
BPMC,BPMC:UW,BBG008D08M37,See what the IHS Markit Score report has to say about Blueprint Medicines Corp.,2017-09-25 12:01:42 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120142037.html?.tsrc=rss,Short interest is low for BPMC with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
BPMC,BPMC:UW,BBG008D08M37,"ETFs with exposure to Blueprint Medicines Corp. : September 19, 2017",2017-09-19 21:07:39 +0000,http://finance.yahoo.com/r/67564708-5906-3a12-b9c1-ee5b4e4d6917/etfs-with-exposure-to-blueprint-medicines-corp-september-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Blueprint Medicines Corp. Here are 5 ETFs with the largest exposure to BPMC-US. Comparing the performance and risk of Blueprint Medicines Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017",2017-09-18 17:08:01 +0000,http://finance.yahoo.com/r/56755f28-6c76-3908-bcad-4288ed778b99/blueprint-medicines-corp-bpmc-us-earnings-analysis-q2-2017-by-the-numbers-september-18-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Blueprint Medicines Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Blueprint Medicines Corp. – Newlink Genetics Corporation and GTx, Inc. (NLNK-US and GTXI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 5.89 million, ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,"TTOO Catches Investors' Eyes, SIEN Shaping Up, AGTC Slips Into Red",2017-09-13 22:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uBXaniUPgaE/ttoo-catches-investors-eyes-sien-shaping-up-agtc-slips-into-red-20170913-01349,"TTOO Catches Investors' Eyes, SIEN Shaping Up, AGTC Slips Into Red"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : September 12, 2017",2017-09-12 15:33:39 +0000,http://finance.yahoo.com/r/04c603b3-7482-3581-9bb3-04521745ff01/blueprint-medicines-corp-breached-its-50-day-moving-average-in-a-bearish-manner-bpmc-us-september-12-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Blueprint Medicines Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,"New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch",2017-09-11 00:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YSrwGw-FWiI/new-hope-for-azns-old-drug-more-about-bmys-opdivo-imdz-on-watch-20170911-00011,"New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma,2017-09-10 14:30:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-announces-data-ongoing-143000352.html?.tsrc=rss,-- Encouraging Clinical Activity Observed in Heavily Pre-Treated Patients with FGFR4-Driven HCC -- -- Data Support Patient Selection Strategy for First Potential Biomarker-Driven Treatment Approach in ...
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at Morgan Stanley 15th Annual Global Healthcare Conference,2017-09-06 12:00:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-present-morgan-stanley-120000165.html?.tsrc=rss,"CAMBRIDGE, Mass. , Sept. 6, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. breached its 50 day moving average in a Bullish Manner : BPMC-US : August 24, 2017",2017-08-24 12:27:12 +0000,http://finance.yahoo.com/r/bb3cc80c-a26e-3cef-afb2-023f45cfdf59/blueprint-medicines-corp-breached-its-50-day-moving-average-in-a-bullish-manner-bpmc-us-august-24-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Blueprint Medicines Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,"Gainers & Losers Of Aug.22: OVID, SNNA, BPMC, ABIO, TOCA...",2017-08-22 22:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fHsap0GIE8w/gainers--losers-of-aug22-ovid-snna-bpmc-abio-toca-20170822-01145,"Gainers & Losers Of Aug.22: OVID, SNNA, BPMC, ABIO, TOCA..."
BPMC,BPMC:UW,BBG008D08M37,"Tuesday's ETF Movers: XBI, GDXJ",2017-08-22 20:38:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/24FAqvdNfuY/tuesdays-etf-movers-xbi-gdxj-cm835603,In trading on Tuesday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 2 3 on the day Components of that ETF showing particular strength include shares of Blueprint Medicines BPMC up about 11 2 and shares of Ziopharm Oncology ZIOP up about 8 3 on the
BPMC,BPMC:UW,BBG008D08M37,"Health Care Sector Update for 08/22/2017: BPMC,CLRB,NSPR",2017-08-22 18:39:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ybRtG9RfslI/health-care-sector-update-for-08222017-bpmcclrbnspr-cm835568,Top Health Care StocksTop Health Care Stocks JNJ 0 65 JNJ 0 65 PFE 1 10 PFE 1 10 ABT 1 90 ABT 1 90 MRK 0 49 MRK 0 49 AMGN 1 25 AMGN 1 25 Health care stocks were enjoying a strong rebound on Tuesday with the NYSE Health Care Index over 0 8 higher while shares of health
BPMC,BPMC:UW,BBG008D08M37,Stocks Show Substantial Move To The Upside - U.S. Commentary,2017-08-22 16:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K2eF8s2XzzA/stocks-show-substantial-move-to-the-upside--us-commentary-20170822-00985,Stocks Show Substantial Move To The Upside - U.S. Commentary
BPMC,BPMC:UW,BBG008D08M37,See what the IHS Markit Score report has to say about Blueprint Medicines Corp.,2017-08-22 12:02:49 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120155081.html?.tsrc=rss,"Short interest is low for BPMC with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last month, ETFs holding BPMC are favorable, with net inflows of $1.91 billion."
BPMC,BPMC:UW,BBG008D08M37,Stocks See Further Upside After Early Advance - U.S. Commentary,2017-08-22 12:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NmfeyIWWWC8/stocks-see-further-upside-after-early-advance--us-commentary-20170822-00799,Stocks See Further Upside After Early Advance - U.S. Commentary
BPMC,BPMC:UW,BBG008D08M37,"FDA Approves IRWD's Gout Drug, It's A Thumbs Up For ALXN In EU, CRME Crushed",2017-08-22 01:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4wjgdJDoGlA/fda-approves-irwds-gout-drug-its-a-thumbs-up-for-alxn-in-eu-crme-crushed-20170822-00025,"FDA Approves IRWD's Gout Drug, It's A Thumbs Up For ALXN In EU, CRME Crushed"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. – Value Analysis (NASDAQ:BPMC) : August 21, 2017",2017-08-21 21:50:32 +0000,http://finance.yahoo.com/r/6ba85bf8-4a14-3cd5-80de-0460c847f40d/blueprint-medicines-corp-value-analysis-nasdaqbpmc-august-21-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Blueprint Medicines Corp. a score of 30. Our analysis is based on comparing Blueprint Medicines Corp. with the following peers – IsoRay, Inc., Newlink Genetics Corporation, GTx, Inc. and Galena Biopharma, Inc. (ISR-US, NLNK-US, GTXI-US and GALE-US). Investment Outlook Blueprint Medicines Corp. has a fundamental score of ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference,2017-08-21 20:30:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-present-updated-data-203000682.html?.tsrc=rss,"- Blueprint Medicines to Host Investor Conference Call and Webcast on September 11, 2017 - CAMBRIDGE, Mass. , Aug. 21, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering ..."
BPMC,BPMC:UW,BBG008D08M37,See what the IHS Markit Score report has to say about Blueprint Medicines Corp.,2017-08-18 12:03:29 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120516718.html?.tsrc=rss,"Short interest is low for BPMC with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last month, ETFs holding BPMC are favorable, with net inflows of $1.15 billion."
BPMC,BPMC:UW,BBG008D08M37,See what the IHS Markit Score report has to say about Blueprint Medicines Corp.,2017-08-17 12:03:55 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120355787.html?.tsrc=rss,Short interest is low for BPMC with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  ETFs that hold BPMC had net inflows of $915 million over the last one-month.
BPMC,BPMC:UW,BBG008D08M37,See what the IHS Markit Score report has to say about Blueprint Medicines Corp.,2017-08-14 12:03:19 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120319772.html?.tsrc=rss,"Short interest is low for BPMC with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BPMC totaled $1.42 billion."
BPMC,BPMC:UW,BBG008D08M37,See what the IHS Markit Score report has to say about Blueprint Medicines Corp.,2017-08-12 12:01:29 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120129855.html?.tsrc=rss,"Short interest is low for BPMC with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BPMC totaled $982 million."
BPMC,BPMC:UW,BBG008D08M37,Edited Transcript of BPMC earnings conference call or presentation 2-Aug-17 12:30pm GMT,2017-08-12 03:36:09 +0000,https://finance.yahoo.com/news/edited-transcript-bpmc-earnings-conference-184130179.html?.tsrc=rss,Q2 2017 Blueprint Medicines Corp Earnings Call
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : August 10, 2017",2017-08-10 13:42:28 +0000,http://finance.yahoo.com/r/aafeaa52-b448-35e8-a51b-64f7c6fe8cda/blueprint-medicines-corp-breached-its-50-day-moving-average-in-a-bearish-manner-bpmc-us-august-10-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Blueprint Medicines Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,See what the IHS Markit Score report has to say about Blueprint Medicines Corp.,2017-08-10 12:01:41 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120141480.html?.tsrc=rss,"Short interest is low for BPMC with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding BPMC totaled $1.32 billion."
BPMC,BPMC:UW,BBG008D08M37,Featured Company News - Galena Biopharma Announces Merger Agreement with SELLAS Life Sciences Group,2017-08-10 11:00:00 +0000,https://finance.yahoo.com/news/featured-company-news-galena-biopharma-110000877.html?.tsrc=rss,"Research Desk Line-up: Blueprint Medicines Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 10, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at Upcoming Investor Conferences in August,2017-08-03 12:00:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-present-upcoming-investor-120000949.html?.tsrc=rss,"CAMBRIDGE, Mass. , Aug. 3, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines reports 2Q loss,2017-08-03 02:34:23 +0000,https://finance.yahoo.com/news/blueprint-medicines-reports-2q-loss-113316062.html?.tsrc=rss,"The Cambridge, Massachusetts-based company said it had a loss of 86 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Reports Second Quarter 2017 Financial Results,2017-08-02 11:00:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-reports-second-quarter-110000240.html?.tsrc=rss,-- BLU-285 granted Breakthrough Therapy Designation for the treatment of patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRα D842V mutation -- -- Announced ...
BPMC,BPMC:UW,BBG008D08M37,Strange: Bullish BPMC Analysts Actually See -3.37% Downside,2017-07-28 13:59:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HgkpgxeRUv4/strange-bullish-bpmc-analysts-actually-see-337-downside-cm823144,Analyst ratings can sometimes be complicated and we here at ETF Channel have noticed a bit of a paradox with Blueprint Medicines Corp Symbol BPMC The average 12 month price target for BPMC averaging the work of 4 analysts reveals an average price target of 50 50 share That s a
BPMC,BPMC:UW,BBG008D08M37,​Alexion cuts ties with two Cambridge biotechs in reorganization,2017-07-27 15:20:14 +0000,http://finance.yahoo.com/r/6ed3b1fc-e660-3c65-8819-d087be536d65/alexion-cuts-ties-with-two-cambridge-biotechs-in.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Alexion Pharmaceuticals said Thursday that it’s scrapping a handful of drug development programs as part of a reorganization, including its partnership deals with a pair of Cambridge biotechs.  Moderna : Alexion’s 2014 deal with Moderna, one of the state’s largest privately-held biotechs, covered treatments that use messenger RNA, or mRNA — molecules that recruit the body's own cells to create proteins to fight rare diseases.  Under that agreement, Alexion paid Moderna $100 million upfront in exchange for the option to partner on up to 10 products."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion,2017-07-27 10:35:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-evaluate-opportunities-advance-103500840.html?.tsrc=rss,"CAMBRIDGE, Mass., July 27, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced plans to evaluate opportunities to advance its rare disease discovery program in fibrodysplasia ossificans progressiva (FOP), which was the subject of Blueprint Medicines' collaboration with Alexion Pharma Holding (Alexion).  On July 26, 2017, Blueprint Medicines received written notice from Alexion of its decision to discontinue the collaboration following a strategic review of Alexion's business and research and development portfolio."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines to Report Second Quarter 2017 Financial Results on Wednesday, August 2, 2017",2017-07-26 12:00:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-report-second-quarter-120000267.html?.tsrc=rss,"CAMBRIDGE, Mass. , July 26, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"ETFs with exposure to Blueprint Medicines Corp. : July 7, 2017",2017-07-07 18:38:20 +0000,http://finance.yahoo.com/r/0f6c691c-035e-3535-a5a4-cb4a1ea65887/etfs-with-exposure-to-blueprint-medicines-corp-july-7-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Blueprint Medicines Corp. Here are 5 ETFs with the largest exposure to BPMC-US. Comparing the performance and risk of Blueprint Medicines Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines (BPMC) Shows Strength: Stock Adds 9.6% in Session,2017-07-06 14:50:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bMYzrVTx1XQ/blueprint-medicines-bpmc-shows-strength-stock-adds-96-in-session-cm812353,Blueprint Medicines Corporation BPMC was a big mover last session as the company saw its shares rise nearly 10 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines (BPMC) Shows Strength: Stock Adds 9.6% in Session,2017-07-06 12:33:12 +0000,https://finance.yahoo.com/news/blueprint-medicines-bpmc-shows-strength-123312634.html?.tsrc=rss,"Blueprint Medicines Corporation (BPMC) was a big mover last session, as the company saw its shares rise nearly 10% on the day."
BPMC,BPMC:UW,BBG008D08M37,"Gainers & Losers Of July 5: CALA, NVRO, BPMC, KMPH, FLDM...",2017-07-05 22:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-sOasuVpC4g/gainers--losers-of-july-5-cala-nvro-bpmc-kmph-fldm-20170705-01206,"Gainers & Losers Of July 5: CALA, NVRO, BPMC, KMPH, FLDM..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Reaches Analyst Target Price,2017-06-27 13:50:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1VWDFc40Cnw/blueprint-medicines-reaches-analyst-target-price-cm808495,In recent trading shares of Blueprint Medicines Corp Symbol BPMC have crossed above the average analyst 12 month target price of 50 50 changing hands for 52 23 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
BPMC,BPMC:UW,BBG008D08M37,"Wednesday's ETF Movers: XBI, XOP",2017-06-21 19:21:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Iusupdyw5eM/wednesdays-etf-movers-xbi-xop-cm806447,In trading on Wednesday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 3 5 on the day Components of that ETF showing particular strength include shares of Esperion Therapeutics ESPR up about 13 1 and shares of Blueprint Medicines BPMC up about 9 9
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. breached its 50 day moving average in a Bullish Manner : BPMC-US : June 21, 2017",2017-06-21 12:07:13 +0000,http://finance.yahoo.com/r/55bdd79e-8789-3552-802f-945ce0dcbcc1/blueprint-medicines-corp-breached-its-50-day-moving-average-in-a-bullish-manner-bpmc-us-june-21-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Blueprint Medicines Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,"​Bluebird and Radius gain, while Blueprint and Tesaro fall, at ASCO cancer summit",2017-06-06 10:30:12 +0000,http://finance.yahoo.com/r/ef1ee849-2e9c-3415-93e7-50e292c95b20/bluebird-and-radius-gain-while-blueprint-and.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Some local biotechs are among the biggest stock market gainers — and losers — so far at this week's closely-watched annual conference in Chicago on cancer drug research.  The annual meeting of the American Society of Clinical Oncology, which began Friday and runs through Tuesday, has featured presentations by companies from across the globe on some of the most promising cancer treatments currently in clinical trials.  The conference comes at a time when oncology R&D is booming: according to one recent report, the number of late-stage cancer drugs has increased by 45 percent over the last decade, while the size and duration of pivotal trials has decreased."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRα D842V Mutation,2017-06-05 12:00:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-announces-phase-1-120000156.html?.tsrc=rss,"CAMBRIDGE, Mass., June 5, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"ETFs with exposure to Blueprint Medicines Corp. : June 1, 2017",2017-06-01 17:40:55 +0000,http://finance.yahoo.com/r/e0094452-f2a0-3bbb-8637-d7a2055c6ccd/etfs-with-exposure-to-blueprint-medicines-corp-june-1-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Blueprint Medicines Corp. Here are 5 ETFs with the largest exposure to BPMC-US. Comparing the performance and risk of Blueprint Medicines Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at Upcoming Investor Conferences in June,2017-06-01 12:00:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-present-upcoming-investor-120000442.html?.tsrc=rss,"CAMBRIDGE, Mass., June 1, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and development targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"SNDX Rises On Entinostat Data, Kalydeco Gets FDA Nod, Concert Fails To Enthrall",2017-05-18 02:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HyPHxNz3ekQ/sndx-rises-on-entinostat-data-kalydeco-gets-fda-nod-concert-fails-to-enthrall-20170518-00073,"SNDX Rises On Entinostat Data, Kalydeco Gets FDA Nod, Concert Fails To Enthrall"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting,2017-05-17 21:01:00 +0000,https://finance.yahoo.com/news/blueprint-medicines-present-data-ongoing-210100619.html?.tsrc=rss,"CAMBRIDGE, Mass., May 17, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and development targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"ETFs with exposure to Blueprint Medicines Corp. : May 8, 2017",2017-05-08 20:14:16 +0000,http://finance.yahoo.com/r/75889ce8-5432-3db2-aee9-15c5ab7b2e52/etfs-with-exposure-to-blueprint-medicines-corp-may-8-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Blueprint Medicines Corp. Here are 5 ETFs with the largest exposure to BPMC-US. Comparing the performance and risk of Blueprint Medicines Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017",2017-05-05 15:21:05 +0000,http://finance.yahoo.com/r/8ca90752-fb8a-3826-b15a-3aa85ef23e24/blueprint-medicines-corp-bpmc-us-earnings-analysis-q1-2017-by-the-numbers-may-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Blueprint Medicines Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Blueprint Medicines Corp. – Newlink Genetics Corporation (NLNK-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 5.84 million, Net Earnings of USD -27.98 ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : May 5, 2017",2017-05-05 12:57:21 +0000,http://finance.yahoo.com/r/00748195-79d9-366e-b822-4c2d59eb794d/blueprint-medicines-corp-breached-its-50-day-moving-average-in-a-bearish-manner-bpmc-us-may-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Blueprint Medicines Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines reports 1Q loss,2017-05-03 11:26:47 +0000,http://finance.yahoo.com/news/blueprint-medicines-reports-1q-loss-112647214.html?.tsrc=rss,"On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 84 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks ..."
BPMC,BPMC:UW,BBG008D08M37,Investor Network: Blueprint Medicines Corp. to Host Earnings Call,2017-05-03 11:15:00 +0000,http://finance.yahoo.com/news/investor-network-blueprint-medicines-corp-111500237.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 3, 2017 / Blueprint Medicines Corp. (NASDAQ: BPMC) will be discussing their earnings results in their Q1 Earnings Call to be held May 3, 2017 at 8:30 AM Eastern Time. To ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Reports First Quarter 2017 Financial Results,2017-05-03 11:00:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-reports-first-quarter-110000261.html?.tsrc=rss,"CAMBRIDGE, Mass., May 3, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,3 Stocks That Could Have Doubled Your Money,2017-04-27 16:12:00 +0000,http://finance.yahoo.com/r/2225ff96-74e0-3533-9034-2fef50855af1/3-stocks-that-could-have-doubled-your-money.aspx?yptr=yahoo&.tsrc=rss,These stocks may yet grow into multibaggers with a little more time.
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines to Report First Quarter 2017 Financial Results on Wednesday, May 3, 2017",2017-04-26 12:00:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-report-first-quarter-120000031.html?.tsrc=rss,"CAMBRIDGE, Mass., April 26, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and audio webcast at 8:30 a.m. ET on Wednesday, May 3, 2017 to report its first quarter 2017 financial results and provide a corporate update.  A webcast of the call will also be available on the Investors section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/.  The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call."
BPMC,BPMC:UW,BBG008D08M37,"Commit To Buy Blueprint Medicines Corp At $40, Earn 18.2% Annualized Using Options",2017-04-07 16:56:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/inFFEu0e3ws/commit-to-buy-blueprint-medicines-corp-at-40-earn-182-annualized-using-options-cm771489,Investors eyeing a purchase of Blueprint Medicines Corp Symbol BPMC shares but cautious about paying the going market price of 46 13 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock,2017-04-04 20:01:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-closing-public-200100920.html?.tsrc=rss,"CAMBRIDGE, Mass., April 4, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $40.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock.  Blueprint Medicines estimates net proceeds from the offering will be approximately $215.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.  Goldman, Sachs & Co., Morgan Stanley and Cowen and Company acted as joint book-running managers for the offering."
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat",2017-03-30 20:46:52 +0000,http://biz.yahoo.com/e/170330/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat"
BPMC,BPMC:UW,BBG008D08M37,"Pre-Market Most Active for Mar 30, 2017 :  CVE, LULU, FTR, DB, TNXP, MT, UN, CRBP, SGYP, BPMC, COP, DNR",2017-03-30 12:59:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MkQXvFE4Ev8/pre-market-most-active-for-mar-30-2017-cve-lulu-ftr-db-tnxp-mt-un-crbp-sgyp-bpmc-cop-dnr-cm767593,The NASDAQ 100 Pre Market Indicator is up 98 to 5 431 25 The total Pre Market volume is currently 11 534 831 shares traded The following are the most active stocks for the pre market session Cenovus Energy Inc CVE is 1 05 at 12 03 with 3 468 242 shares traded CVE
BPMC,BPMC:UW,BBG008D08M37,7:01 pm Blueprint Medicines prices 5 mln share common stock offering at $40.00 per share,2017-03-29 23:01:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#bpmc,7:01 pm Blueprint Medicines prices 5 mln share common stock offering at $40.00 per share
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock,2017-03-29 22:55:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-pricing-public-225500984.html,"[PR Newswire] - CAMBRIDGE, Mass., March 29, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. Goldman, Sachs & Co., Morgan Stanley and Cowen and Company are acting as joint book-running managers for the offering. Raymond James is acting as co-manager for the offering. The offering is expected to close on or about April 4, 2017, subject to the satisfaction of customary closing conditions. A registration statement on Form S-3 (File No. 333-216573) relating to these securities has been previously filed with and declared effective by the Securities and Exchange Commission (SEC)."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock,2017-03-29 22:55:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-pricing-public-225500984.html?.tsrc=rss,"CAMBRIDGE, Mass., March 29, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions.  Goldman, Sachs & Co., Morgan Stanley and Cowen and Company are acting as joint book-running managers for the offering.  Raymond James is acting as co-manager for the offering.  The offering is expected to close on or about April 4, 2017, subject to the satisfaction of customary closing conditions.  A registration statement on Form S-3 (File No. 333-216573) relating to these securities has been previously filed with and declared effective by the Securities and Exchange Commission (SEC)."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock,2017-03-29 11:30:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-proposed-public-113000342.html,"[PR Newswire] - CAMBRIDGE, Mass., March 29, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has commenced an underwritten public offering of $150,000,000 in shares of its common stock. In addition, Blueprint Medicines expects to grant the underwriters a 30-day option to purchase up to an additional of $22,500,000 in shares of its common stock in connection with the public offering. Blueprint Medicines expects to use the net proceeds of the offering to fund clinical trials for BLU-285 in GIST and SM, to fund clinical trials for BLU-554 in HCC, to fund the completion of its current Phase 1 clinical trial for BLU-667 in non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors and the initiation of additional clinical trials for BLU-667 in RET-driven cancers, and the balance, if any, to fund working capital, and other general corporate purposes, including ongoing research and pre-commercial planning activities."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock,2017-03-29 11:30:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-proposed-public-113000342.html?.tsrc=rss,"CAMBRIDGE, Mass., March 29, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has commenced an underwritten public offering of $150,000,000 in shares of its common stock.  In addition, Blueprint Medicines expects to grant the underwriters a 30-day option to purchase up to an additional of $22,500,000 in shares of its common stock in connection with the public offering.  Blueprint Medicines expects to use the net proceeds of the offering to fund clinical trials for BLU-285 in GIST and SM, to fund clinical trials for BLU-554 in HCC, to fund the completion of its current Phase 1 clinical trial for BLU-667 in non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors and the initiation of additional clinical trials for BLU-667 in RET-driven cancers, and the balance, if any, to fund working capital, and other general corporate purposes, including ongoing research and pre-commercial planning activities."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences,2017-03-27 20:01:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-present-blu-285-200100793.html,"[PR Newswire] - CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences,2017-03-27 20:01:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-present-blu-285-200100793.html?.tsrc=rss,"CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,3 Biotech Stocks That Are Broker Favorites,2017-03-21 15:11:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nu2Z5LqTpbM/3-biotech-stocks-that-are-broker-favorites-cm763530,Biotech stocks which have been showing signs of recovery this year slipped last week following the release of the Budget Blueprint for 2018 Amgen s AMGN data on its PCSK9 inhibitor Repatha and a couple of analyst downgrades for Biogen BIIB Budget Calls for Higher Fees Even
BPMC,BPMC:UW,BBG008D08M37,3 Biotech Stocks That Are Broker Favorites,2017-03-21 13:25:01 +0000,http://finance.yahoo.com/news/3-biotech-stocks-broker-favorites-132501079.html,3 Biotech Stocks That Are Broker Favorites
BPMC,BPMC:UW,BBG008D08M37,3 Biotech Stocks That Are Broker Favorites,2017-03-21 13:25:01 +0000,http://finance.yahoo.com/news/3-biotech-stocks-broker-favorites-132501079.html?.tsrc=rss,These 3 biotech stocks have been given a Strong Buy or Buy rating by 80% or more brokers and sport a favorable Zacks Rank #1 (Strong Buy) or #2 (Buy).
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667,2017-03-20 20:01:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-enrollment-first-200100001.html,"[PR Newswire] - CAMBRIDGE, Mass., March 20, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has dosed the first patient in a Phase 1 clinical trial of BLU-667, an investigational RET inhibitor for patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other advanced solid tumors that harbor a RET alteration. ""By rapidly initiating a clinical trial for our potent and selective RET inhibitor BLU-667, we have successfully achieved a key 2017 milestone,"" said Jeff Albers, Chief Executive Officer of Blueprint Medicines. ""This continued progress underscores our commitment to build Blueprint Medicines into a sustainable company."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667,2017-03-20 20:01:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-enrollment-first-200100001.html?.tsrc=rss,"CAMBRIDGE, Mass., March 20, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has dosed the first patient in a Phase 1 clinical trial of BLU-667, an investigational RET inhibitor for patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other advanced solid tumors that harbor a RET alteration.  ""By rapidly initiating a clinical trial for our potent and selective RET inhibitor BLU-667, we have successfully achieved a key 2017 milestone,"" said Jeff Albers, Chief Executive Officer of Blueprint Medicines.  ""This continued progress underscores our commitment to build Blueprint Medicines into a sustainable company."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017",2017-03-17 16:14:24 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-bpmc-us-earnings-analysis-q4-2016-by-the-numbers-march-17-2017/,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017",2017-03-17 16:14:24 +0000,http://finance.yahoo.com/r/32240a05-8396-322b-a37d-59df4498dc99/blueprint-medicines-corp-bpmc-us-earnings-analysis-q4-2016-by-the-numbers-march-17-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Blueprint Medicines Corp. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Blueprint Medicines Corp. – IsoRay, Inc., Newlink Genetics Corporation, GTx, Inc. and Galena Biopharma, Inc. (ISR-US, NLNK-US, GTXI-US and GALE-US) that have also reported for this period. Highlights ... Read more    
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,BLUEPRINT MEDICINES CORP Financials,2017-03-15 17:04:09 +0000,http://finance.yahoo.com/q/is?s=bpmc,BLUEPRINT MEDICINES CORP Financials
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017",2017-03-15 16:09:44 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-bpmc-us-earnings-analysis-2016-by-the-numbers-march-15-2017/,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017",2017-03-15 16:09:44 +0000,http://finance.yahoo.com/r/788c2db8-b21e-31c8-b09d-093aad5c7750/blueprint-medicines-corp-bpmc-us-earnings-analysis-2016-by-the-numbers-march-15-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Blueprint Medicines Corp. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Blueprint Medicines Corp. – IsoRay, Inc. and Newlink Genetics Corporation (ISR-US and NLNK-US) that have also reported for this period. Highlights Year-on-year change in operating cash flow of ... Read more    
<b>(Read more...)</b>"
BPMC,BPMC:UW,BBG008D08M37,Can The Uptrend Continue for Blueprint Medicines (BPMC)?,2017-03-14 16:07:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TrG5psTjL5o/can-the-uptrend-continue-for-blueprint-medicines-bpmc-cm760544,Investors certainly have to be happy with Blueprint Medicines Corporation BPMC and its short term performance After all the stock has jumped by 20 5 in the past 4 weeks and it is also above its 20 Day Simple Moving Average as well This is certainly a good trend but investors are
BPMC,BPMC:UW,BBG008D08M37,Can The Uptrend Continue for Blueprint Medicines (BPMC)?,2017-03-14 14:14:02 +0000,http://finance.yahoo.com/news/uptrend-continue-blueprint-medicines-bpmc-141402336.html?.tsrc=rss,Investors certainly have to be happy with Blueprint Medicines Corporation (BPMC) and its short term performance
BPMC,BPMC:UW,BBG008D08M37,Can The Uptrend Continue for Blueprint Medicines (BPMC)?,2017-03-14 14:14:02 +0000,http://finance.yahoo.com/news/uptrend-continue-blueprint-medicines-bpmc-141402336.html,Can The Uptrend Continue for Blueprint Medicines (BPMC)?
BPMC,BPMC:UW,BBG008D08M37,"Analysts' Actions -- Boeing, Blueprint Medicines, Rockwell Collins, Johnson Controls and More",2017-03-13 13:43:00 +0000,http://finance.yahoo.com/news/analysts-actions-boeing-blueprint-medicines-134300847.html?.tsrc=rss,"Here are Monday's top research calls, including upgrades for Blueprint Medicine, Gartner and Rockwell Collins and a downgrade for Boeing."
BPMC,BPMC:UW,BBG008D08M37,"Analysts' Actions -- Boeing, Blueprint Medicines, Rockwell Collins, Johnson Controls and More",2017-03-13 13:43:00 +0000,http://finance.yahoo.com/news/analysts-actions-boeing-blueprint-medicines-134300847.html,"Analysts' Actions -- Boeing, Blueprint Medicines, Rockwell Collins, Johnson Controls and More"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines upgraded by Goldman,2017-03-13 10:03:17 +0000,http://finance.yahoo.com/q/ud?s=BPMC,Blueprint Medicines upgraded by Goldman
BPMC,BPMC:UW,BBG008D08M37,Edited Transcript of BPMC earnings conference call or presentation 9-Mar-17 1:30pm GMT,2017-03-10 14:41:09 +0000,http://finance.yahoo.com/news/edited-transcript-bpmc-earnings-conference-144109033.html?.tsrc=rss,Q4 2016 Blueprint Medicines Corp Earnings Call
BPMC,BPMC:UW,BBG008D08M37,Edited Transcript of BPMC earnings conference call or presentation 9-Mar-17 1:30pm GMT,2017-03-10 14:41:09 +0000,http://finance.yahoo.com/news/edited-transcript-bpmc-earnings-conference-144109033.html,Edited Transcript of BPMC earnings conference call or presentation 9-Mar-17 1:30pm GMT
BPMC,BPMC:UW,BBG008D08M37,6 Stocks on the Move With Huge Volume,2017-03-10 11:30:00 +0000,https://www.thestreet.com/story/14036163/1/6-stocks-on-the-move-with-huge-volume.html?puc=yahoo&cm_ven=YAHOO,6 Stocks on the Move With Huge Volume
BPMC,BPMC:UW,BBG008D08M37,6 Stocks on the Move With Huge Volume,2017-03-10 11:30:00 +0000,http://finance.yahoo.com/r/ce97af8a-ac2c-3214-a7e5-82e89e1b24b8/6-stocks-on-the-move-with-huge-volume.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Here's a technical look at how to play a number of stocks trending higher with strong volume.
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Corp Earnings Call scheduled for 8:30 am ET today,2017-03-09 13:30:00 +0000,http://biz.yahoo.com/cc/7/156007.html,Blueprint Medicines Corp Earnings Call scheduled for 8:30 am ET today
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2017-03-09 12:32:53 +0000,http://biz.yahoo.com/e/170309/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines reports 4Q loss,2017-03-09 12:26:50 +0000,http://sg.finance.yahoo.com/news/blueprint-medicines-reports-4q-loss-122449922.html,Blueprint Medicines reports 4Q loss
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines reports 4Q loss,2017-03-09 12:26:50 +0000,http://finance.yahoo.com/news/blueprint-medicines-reports-4q-loss-122449198.html?.tsrc=rss,"The Cambridge, Massachusetts-based company said it had a loss of 75 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ..."
BPMC,BPMC:UW,BBG008D08M37,Q4 2016 Blueprint Medicines Corp Earnings Release - Before Market Open,2017-03-09 12:07:03 +0000,http://biz.yahoo.com/research/earncal/20170309.html?t=bpmc,Q4 2016 Blueprint Medicines Corp Earnings Release - Before Market Open
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results,2017-03-09 12:00:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-reports-fourth-quarter-120000253.html,"[PR Newswire] - CAMBRIDGE, Mass., March 9, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results,2017-03-09 12:00:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-reports-fourth-quarter-120000253.html?.tsrc=rss,"CAMBRIDGE, Mass., March 9, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"Pre-Market Earnings Report for March 9, 2017 :  SPLS, IGT, SIG, ERJ, FMSA, PRTY, BPMC, EGL, SSYS, EPZM, PGNX, GLP",2017-03-08 21:13:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w0YTMNkKzt0/pre-market-earnings-report-for-march-9-2017-spls-igt-sig-erj-fmsa-prty-bpmc-egl-ssys-epzm-pgnx-glp-cm758127,The following companies are expected to report earnings prior to market open on 03 09 2017 Visit our Earnings Calendar for a full list of expected earnings releases Staples Inc SPLS is reporting for the quarter ending January 31 2017 The retail company
BPMC,BPMC:UW,BBG008D08M37,Should You Buy Blueprint Medicines (BPMC) Ahead of Earnings?,2017-03-08 15:16:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pj-5TnqCkKU/should-you-buy-blueprint-medicines-bpmc-ahead-of-earnings-cm757903,Investors are always looking for stocks that are poised to beat at earnings season and Blueprint Medicines Corporation BPMC may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Blueprint Medicines is
BPMC,BPMC:UW,BBG008D08M37,Should You Buy Blueprint Medicines (BPMC) Ahead of Earnings?,2017-03-08 13:40:01 +0000,http://finance.yahoo.com/news/buy-blueprint-medicines-bpmc-ahead-134001999.html?.tsrc=rss,Investors are always looking for stocks that are poised to beat at earnings season and Blueprint Medicines Corporation (BPMC) may be one such company.
BPMC,BPMC:UW,BBG008D08M37,Should You Buy Blueprint Medicines (BPMC) Ahead of Earnings?,2017-03-08 13:40:01 +0000,http://finance.yahoo.com/news/buy-blueprint-medicines-bpmc-ahead-134001999.html,Should You Buy Blueprint Medicines (BPMC) Ahead of Earnings?
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, March 9, 2017",2017-03-02 13:00:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-report-fourth-quarter-130000454.html?.tsrc=rss,"CAMBRIDGE, Mass., March 2, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 9, 2017 to report its fourth quarter and full year 2016 financial results and provide a corporate update.  A webcast of the call will also be available on the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com.  The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, March 9, 2017",2017-03-02 13:00:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-report-fourth-quarter-130000454.html,"[PR Newswire] - CAMBRIDGE, Mass., March 2, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 9, 2017 to report its fourth quarter and full year 2016 financial results and provide a corporate update. A webcast of the call will also be available on the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at Upcoming Investor Conferences in March,2017-02-28 13:00:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-present-upcoming-investor-130000588.html,"[PR Newswire] - CAMBRIDGE, Mass., Feb. 28, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at Upcoming Investor Conferences in March,2017-02-28 13:00:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-present-upcoming-investor-130000588.html?.tsrc=rss,"CAMBRIDGE, Mass., Feb. 28, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"Boxer Capital, LLC Buys AveXis, BeiGene, Alnylam Pharmaceuticals, Sells Biomarin ...",2017-02-17 20:51:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XwYgiiI0jBI/boxer-capital-llc-buys-avexis-beigene-alnylam-pharmaceuticals-sells-biomarin-cm749825,Boxer Capital LLC New Purchases ALNY ALXN SBBP SNSS BLPH RXDX Added Positions AVXS BGNE MDCO Reduced Positions SGEN CLVS ARDM Sold Out BMRN RIGL HRTX EBIO EPIX New Purchases ALNY ALXN SBBP SNSS BLPH RXDX
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at 2017 RBC Capital Markets Global Healthcare Conference,2017-02-15 13:00:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-present-2017-rbc-130000065.html,"[PR Newswire] - CAMBRIDGE, Mass., Feb. 15, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at 2017 RBC Capital Markets Global Healthcare Conference,2017-02-15 13:00:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-present-2017-rbc-130000065.html?.tsrc=rss,"CAMBRIDGE, Mass., Feb. 15, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,Zimmer Biomet (ZBH) Q4 Earnings: A Surprise in the Cards?,2017-01-17 13:38:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rBllWU9ptR8/zimmer-biomet-zbh-q4-earnings-a-surprise-in-the-cards-cm734050,Orthopedic reconstructive products manufacturer 160 Zimmer Biomet Holdings Inc ZBH is expected to report fourth quarter 2017 financial numbers on Jan 31 before the opening bell 160 Last quarter the company s earnings met the Zacks Consensus Estimate However the four quarter
BPMC,BPMC:UW,BBG008D08M37,Quest Diagnostics (DGX) Q4 Earnings: What Lies in Store?,2017-01-16 15:40:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cjMnVgazjfA/quest-diagnostics-dgx-q4-earnings-what-lies-in-store-cm733885,Quest Diagnostics Inc DGX is scheduled to report fourth quarter and full year 2016 earnings results before the opening bell on Jan 26 2017 Last quarter the company surpassed the Zacks Consensus Estimate for earnings by 2 cents delivering a positive earnings surprise of 1 48 It is
BPMC,BPMC:UW,BBG008D08M37,Mead Johnson (MJN) Q4 Earnings: Disappointment in Store?,2017-01-16 14:40:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OEvCSdif28Y/mead-johnson-mjn-q4-earnings-disappointment-in-store-cm733823,Mead Johnson Nutrition Company MJN is scheduled to report fourth quarter 2016 results on Jan 26 before the opening bell Last quarter the company posted a positive earnings surprise of 1 16 Further Mead Johnson s earnings outpaced the Zacks Consensus Estimate in the past four quarters
BPMC,BPMC:UW,BBG008D08M37,Mead Johnson (MJN) Q4 Earnings: Disappointment in Store?,2017-01-16 12:15:12 +0000,http://finance.yahoo.com/news/mead-johnson-mjn-q4-earnings-121512919.html,Mead Johnson (MJN) Q4 Earnings: Disappointment in Store?
BPMC,BPMC:UW,BBG008D08M37,ResMed (RMD) Q2 Earnings: Disappointment in the Cards?,2017-01-13 13:39:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G5a_YSk0ZRU/resmed-rmd-q2-earnings-disappointment-in-the-cards-cm733122,ResMed Inc RMD is slated to report second quarter fiscal 2017 results after market close on Jan 23 Last quarter the company posted a negative earnings surprise of 1 59 However ResMed s earnings outpaced the Zacks Consensus Estimate in one of the past four quarters with an average beat
BPMC,BPMC:UW,BBG008D08M37,ResMed (RMD) Q2 Earnings: Disappointment in the Cards?,2017-01-13 11:37:11 +0000,http://finance.yahoo.com/news/resmed-rmd-q2-earnings-disappointment-113711385.html,ResMed (RMD) Q2 Earnings: Disappointment in the Cards?
BPMC,BPMC:UW,BBG008D08M37,Analyst: Government wouldn't want to kill goose that lays...,2017-01-11 18:47:00 +0000,http://finance.yahoo.com/video/analyst-government-wouldnt-want-kill-184700528.html?.tsrc=rss,"Michael King, JMP Securities senior analyst, weighs in on the biotech sector as President-elect Donald Trump puts the pharmaceutical industry in his cross hairs, calling it &quot;disastrous.&quot;"
BPMC,BPMC:UW,BBG008D08M37,Analyst: Government wouldn't want to kill goose that lays...,2017-01-11 18:47:00 +0000,http://finance.yahoo.com/video/analyst-government-wouldnt-want-kill-184700528.html,Analyst: Government wouldn't want to kill goose that lays...
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. – Value Analysis (NASDAQ:BPMC) : January 9, 2017",2017-01-09 15:38:43 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-value-analysis-nasdaqbpmc-january-9-2017/,"Blueprint Medicines Corp. – Value Analysis (NASDAQ:BPMC) : January 9, 2017"
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2017-01-09 14:02:06 +0000,http://biz.yahoo.com/e/170109/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines (BPMC) Shares March Higher, Can It Continue?",2017-01-06 16:41:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o29LUVc8Iuw/blueprint-medicines-bpmc-shares-march-higher-can-it-continue-cm730400,Blueprint Medicines Corporation BPMC has been on the move lately as the stock has risen by 10 8 in the past four weeks and it is currently trading well above its 20 Day SMA This is a pretty solid move higher but the question that has to be on investors minds right now is can this
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines (BPMC) Shares March Higher, Can It Continue?",2017-01-06 14:16:02 +0000,http://finance.yahoo.com/news/blueprint-medicines-bpmc-shares-march-141602512.html,"Blueprint Medicines (BPMC) Shares March Higher, Can It Continue?"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. breached its 50 day moving average in a Bullish Manner : BPMC-US : January 6, 2017",2017-01-06 12:38:37 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-breached-its-50-day-moving-average-in-a-bullish-manner-bpmc-us-january-6-2017/,"Blueprint Medicines Corp. breached its 50 day moving average in a Bullish Manner : BPMC-US : January 6, 2017"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines (BPMC): Strong Industry, Solid Earnings Estimate Revisions",2016-12-23 15:58:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0tVS7pTK5Ec/blueprint-medicines-bpmc-strong-industry-solid-earnings-estimate-revisions-cm725614,One stock that might be an intriguing choice for investors right now is Blueprint Medicines Corporation BPMC This is because this security in the Medical Biomedical and Genetics space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines (BPMC): Strong Industry, Solid Earnings Estimate Revisions",2016-12-23 14:20:02 +0000,http://finance.yahoo.com/news/blueprint-medicines-bpmc-strong-industry-142002224.html,"Blueprint Medicines (BPMC): Strong Industry, Solid Earnings Estimate Revisions"
BPMC,BPMC:UW,BBG008D08M37,Is Apptio Inc (APTI) Worthy of Your Portfolio?,2016-12-14 18:07:02 +0000,http://www.insidermonkey.com/blog/is-apptio-inc-apti-worthy-of-your-portfolio-508916/,Is Apptio Inc (APTI) Worthy of Your Portfolio?
BPMC,BPMC:UW,BBG008D08M37,How Blueprint Medicines Corp (BPMC) Stacks Up Against Its Peers,2016-12-14 06:24:24 +0000,http://www.insidermonkey.com/blog/how-blueprint-medicines-corp-bpmc-stacks-up-against-its-peers-508489/,How Blueprint Medicines Corp (BPMC) Stacks Up Against Its Peers
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock,2016-12-13 21:01:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-closing-public-210100709.html,"[PR Newswire] - CAMBRIDGE, Mass., Dec. 13, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $25.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock. Blueprint Medicines estimates net proceeds from the offering will be approximately $134.5 million, after deducting underwriting discounts and commissions and estimated offering expenses. Goldman, Sachs & Co., Morgan Stanley and Cowen and Company acted as joint book-running managers for the offering."
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat",2016-12-08 22:16:11 +0000,http://biz.yahoo.com/e/161208/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat"
BPMC,BPMC:UW,BBG008D08M37,"Health Care Sector Update for 12/08/2016: BPMC,VYGR,OHRP",2016-12-08 18:35:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h3pEw0a88f4/health-care-sector-update-for-12082016-bpmcvygrohrp-cm718816,Top Health Care StocksTop Health Care Stocks JNJ 0 08 JNJ 0 08 PFE 0 80 PFE 0 80 MRK 0 63 MRK 0 63 ABT 0 14 ABT 0 14 AMGN 0 75 AMGN 0 75 Health care stocks were mixed Thursday with the NYSE Health Care Index falling about 0 1 while shares of health care companies in the S amp P
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock,2016-12-07 23:44:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-pricing-public-234400619.html,"[PR Newswire] - CAMBRIDGE, Mass., Dec. 7, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $25.00 per share, before underwriting discounts and commissions. Goldman, Sachs & Co., Morgan Stanley and Cowen and Company are acting as joint book-running managers for the offering. A registration statement on Form S-3 (File No. 333-211266) relating to these securities has been previously filed with and declared effective by the Securities and Exchange Commission (SEC)."
BPMC,BPMC:UW,BBG008D08M37,"Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers",2016-12-07 21:28:00 +0000,https://www.thestreet.com/story/13918283/1/biotech-only-sector-in-the-red-as-trump-vows-to-crackdown-on-drug-pricing-biggest-movers.html?puc=yahoo&cm_ven=YAHOO,"Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers"
BPMC,BPMC:UW,BBG008D08M37,"Wednesday Sector Laggards: Drugs, Biotechnology Stocks",2016-12-07 18:56:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NfceRJdoDV4/wednesday-sector-laggards-drugs-biotechnology-stocks-cm718164,In trading on Wednesday drugs shares were relative laggards down on the day by about 2 7 Helping drag down the group were shares of Repros Therapeutics RPRX down about 10 5 and shares of Blueprint Medicines BPMC down about 9 6 on the day Also lagging the market Wednesday
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock,2016-12-06 21:26:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-proposed-public-212600917.html,"[PR Newswire] - CAMBRIDGE, Mass., Dec. 6, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has commenced an underwritten public offering of $125,000,000 million in shares of its common stock. In addition, Blueprint Medicines expects to grant the underwriters a 30-day option to purchase up to an additional of $18,750,000 million in shares of its common stock in connection with the public offering."
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-12-05 14:07:27 +0000,http://biz.yahoo.com/e/161205/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Conference Call, ASH Annual Meeting & Expedition scheduled for 8:00 am ET today",2016-12-05 13:00:00 +0000,http://biz.yahoo.com/cc/9/154779.html,"Blueprint Medicines Conference Call, ASH Annual Meeting & Expedition scheduled for 8:00 am ET today"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis,2016-12-05 00:30:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-proof-concept-003000093.html,"[PR Newswire] - CAMBRIDGE, Mass., Dec. 4, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced data from its ongoing Phase 1 trial evaluating BLU-285, an investigational medicine for the treatment of patients with advanced systemic mastocytosis (SM). Blueprint Medicines is developing BLU-285 as a potent, highly selective inhibitor of D816V mutant KIT. Approximately 90 to 95 percent of patients with SM are estimated to have the KIT D816V mutation, the key driver of SM that triggers the abnormal proliferation and survival of mast cells. The data are being presented today at the 2016 American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Corp EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Call scheduled for 12:30 pm ET today,2016-12-01 17:30:00 +0000,http://biz.yahoo.com/cc/9/154969.html,Blueprint Medicines Corp EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Call scheduled for 12:30 pm ET today
BPMC,BPMC:UW,BBG008D08M37,"ETFs with exposure to Blueprint Medicines Corp. : December 1, 2016",2016-12-01 15:50:33 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-blueprint-medicines-corp-december-1-2016/,"ETFs with exposure to Blueprint Medicines Corp. : December 1, 2016"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors,2016-12-01 15:22:20 +0000,http://www.publicnow.com/view/F2BAFD97A6A650BE0324EC0B6D4746BCAADAAC55,"[at noodls] - CAMBRIDGE, Mass., Nov. 30, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"It's All Green For BLUE, HTBX Plunges On Failed Study, Watch Out For BPMC",2016-12-01 00:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tDge2q3p8Iw/its-all-green-for-blue-htbx-plunges-on-failed-study-watch-out-for-bpmc-20161201-00015,"It's All Green For BLUE, HTBX Plunges On Failed Study, Watch Out For BPMC"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors,2016-11-30 23:01:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-proof-concept-230100722.html,"[PR Newswire] - CAMBRIDGE, Mass., Nov. 30, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : November 30, 2016",2016-11-30 12:35:28 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-breached-its-50-day-moving-average-in-a-bearish-manner-bpmc-us-november-30-2016/,"Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : November 30, 2016"
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-11-29 13:32:20 +0000,http://biz.yahoo.com/e/161129/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Proof-of-Concept Data from Global Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma,2016-11-28 23:01:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-proof-concept-230100829.html,"[PR Newswire] - CAMBRIDGE, Mass., Nov. 28, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016",2016-11-18 14:41:03 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-bpmc-us-earnings-analysis-q3-2016-by-the-numbers-november-18-2016/,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trials for BLU-285 and BLU-554 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics,2016-11-15 11:08:06 +0000,http://www.publicnow.com/view/44C338279CCB90D930F7A9EA5B3BD3D34CEE722D,"[at noodls] - CAMBRIDGE, Mass., Nov. 15, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi",2016-11-14 22:42:37 +0000,http://biz.yahoo.com/e/161114/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role",2016-11-14 21:07:15 +0000,http://www.publicnow.com/view/428D553B32DA625245E861840A70C016648A9721,"[at noodls] - CAMBRIDGE, Mass., Nov. 14, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,Edited Transcript of BPMC earnings conference call or presentation 10-Nov-16 1:30pm GMT,2016-11-12 01:18:16 +0000,http://finance.yahoo.com/news/edited-transcript-bpmc-earnings-conference-011816950.html,Edited Transcript of BPMC earnings conference call or presentation 10-Nov-16 1:30pm GMT
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-11-10 12:31:29 +0000,http://biz.yahoo.com/e/161110/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Reports Third Quarter 2016 Financial Results,2016-11-10 12:11:05 +0000,http://www.publicnow.com/view/28C76985577EA0AEFD8B9610A6CB951DA5CA8B09,"[at noodls] - CAMBRIDGE, Mass., Nov. 10, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines reports 3Q loss,2016-11-10 12:09:25 +0000,http://sg.finance.yahoo.com/news/blueprint-medicines-reports-3q-loss-120925762.html,Blueprint Medicines reports 3Q loss
BPMC,BPMC:UW,BBG008D08M37,Q3 2016 Blueprint Medicines Corp Earnings Release - Time Not Supplied,2016-11-10 12:07:07 +0000,http://biz.yahoo.com/research/earncal/20161110.html?t=bpmc,Q3 2016 Blueprint Medicines Corp Earnings Release - Time Not Supplied
BPMC,BPMC:UW,BBG008D08M37,"Drug Stocks Q3 Earnings Roster for Nov 10: AVXS, GBT & BPMC",2016-11-09 14:56:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MPshT4BFZf4/drug-stocks-q3-earnings-roster-for-nov-10-avxs-gbt-bpmc-cm706265,The bulk of the Q3 earnings season is over with 423 S amp P 500 members as of Nov 4 accounting for 87 1 of the index s total market capitalization having already reported results according to the latest Earnings Preview While total earnings for these index members were up 3 6 from
BPMC,BPMC:UW,BBG008D08M37,"Drug Stocks Q3 Earnings Roster for Nov 10: AVXS, GBT & BPMC",2016-11-09 13:10:01 +0000,http://finance.yahoo.com/news/drug-stocks-q3-earnings-roster-131001723.html,"Drug Stocks Q3 Earnings Roster for Nov 10: AVXS, GBT & BPMC"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines to Report Third Quarter 2016 Financial Results on Thursday, November 10, 2016",2016-11-03 20:09:35 +0000,http://www.publicnow.com/view/DE715E4CDC9A9DD480D1C159908B1B2D2191BD6D,"[at noodls] - CAMBRIDGE, Mass., Nov. 3, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at 2016 ASH Annual Meeting,2016-11-03 13:18:12 +0000,http://www.publicnow.com/view/2E4BEA842866642E95956D842936EE8D0EC7571B,"[at noodls] - CAMBRIDGE, Mass., Nov. 3, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : November 3, 2016",2016-11-03 12:31:37 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-breached-its-50-day-moving-average-in-a-bearish-manner-bpmc-us-november-3-2016/,"Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : November 3, 2016"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Corp (BPMC) Stock: Deerfield Management Reports New 4.51% Stake,2016-10-27 14:36:55 +0000,http://www.insidermonkey.com/blog/blueprint-medicines-corp-bpmc-stock-deerfield-management-reports-new-4-51-stake-483151/,Blueprint Medicines Corp (BPMC) Stock: Deerfield Management Reports New 4.51% Stake
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President,2016-09-17 09:38:09 +0000,http://www.publicnow.com/view/B8AB216627AE94120FEEFAAB640FA15FB98B06B7,"[at noodls] - CAMBRIDGE, Mass., Sept. 6, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective investigational kinase medicines for patients with ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces New Drug Discovery Program Targeting PRKACA Kinase Fusions for the Treatment of Fibrolamellar Carcinoma at 10th International Liver Cancer Association (ILCA) Annual Conference,2016-09-09 12:30:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-announces-drug-discovery-123000109.html,"[PR Newswire] - CAMBRIDGE, Mass., Sept. 9, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today disclosed a new drug discovery program targeting protein kinase cAMP-activated catalytic subunit alpha (PRKACA) fusions for the treatment of fibrolamellar carcinoma (FLC). The announcement was made during an oral presentation on September 8, 2016 at the 10th ILCA Annual Conference in Vancouver, Canada on Blueprint Medicines' efforts to develop targeted therapies for patients with hepatocellular carcinoma. ""Patients with liver cancers have historically suffered from a lack of genomically defined therapeutic options."
BPMC,BPMC:UW,BBG008D08M37,"ETF’s with exposure to Blueprint Medicines Corp. : September 8, 2016",2016-09-08 14:08:40 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-blueprint-medicines-corp-september-8-2016/,"ETF’s with exposure to Blueprint Medicines Corp. : September 8, 2016"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at Morgan Stanley Global Healthcare Conference,2016-09-07 12:30:00 +0000,http://finance.yahoo.com/news/blueprint-medicines-present-morgan-stanley-123000924.html,"[PR Newswire] - CAMBRIDGE, Mass., Sept. 7, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi",2016-09-06 21:22:04 +0000,http://biz.yahoo.com/e/160906/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President,2016-09-06 20:19:01 +0000,http://www.publicnow.com/view/B413695EA3843557A4B56D611E639562257E810D,"[at noodls] - CAMBRIDGE, Mass., Sept. 6, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective investigational kinase medicines for patients with ..."
BPMC,BPMC:UW,BBG008D08M37,ITT Tech Schools Go Bust,2016-09-06 16:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VRs9OWPiZhg/itt-tech-schools-go-bust-20160906-01143,ITT Tech Schools Go Bust
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement",2016-08-23 21:02:13 +0000,http://biz.yahoo.com/e/160823/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement"
BPMC,BPMC:UW,BBG008D08M37,"ETF’s with exposure to Blueprint Medicines Corp. : August 23, 2016",2016-08-23 15:28:11 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-blueprint-medicines-corp-august-23-2016/,"ETF’s with exposure to Blueprint Medicines Corp. : August 23, 2016"
BPMC,BPMC:UW,BBG008D08M37,Why Blueprint Medicines (BPMC) Stock Might be a Great Pick,2016-08-16 16:41:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2BdhFe8vMY4/why-blueprint-medicines-bpmc-stock-might-be-a-great-pick-cm665990,"One stock that might be an intriguing choice for investors right now is Blueprint Medicines CorporationBPMC .This is because this security in the Medical Biomedical Genetics space is seeing solid earnings estimate revision activity, and is in great company"
BPMC,BPMC:UW,BBG008D08M37,Why Blueprint Medicines (BPMC) Stock Might be a Great Pick,2016-08-16 14:21:02 +0000,http://finance.yahoo.com/news/why-blueprint-medicines-bpmc-stock-142102340.html,Why Blueprint Medicines (BPMC) Stock Might be a Great Pick
BPMC,BPMC:UW,BBG008D08M37,Edited Transcript of BPMC earnings conference call or presentation 9-Aug-16 12:30pm GMT,2016-08-10 16:58:39 +0000,http://finance.yahoo.com/news/edited-transcript-bpmc-earnings-conference-165839275.html,Edited Transcript of BPMC earnings conference call or presentation 9-Aug-16 12:30pm GMT
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016",2016-08-10 16:06:17 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-bpmc-us-earnings-analysis-q2-2016-by-the-numbers-august-10-2016/,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016"
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-08-09 11:31:49 +0000,http://biz.yahoo.com/e/160809/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines reports 2Q loss,2016-08-09 11:31:25 +0000,http://sg.finance.yahoo.com/news/blueprint-medicines-reports-2q-loss-113125628.html,Blueprint Medicines reports 2Q loss
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Reports Second Quarter 2016 Financial Results,2016-08-09 11:30:14 +0000,http://www.publicnow.com/view/5CAF1871D5B3133EF8A084E22EF282D447830F0C,"[at noodls] - CAMBRIDGE, Mass., Aug. 9, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,Q2 2016 Blueprint Medicines Corp Earnings Release - Time Not Supplied,2016-08-09 11:07:03 +0000,http://biz.yahoo.com/research/earncal/20160809.html?t=bpmc,Q2 2016 Blueprint Medicines Corp Earnings Release - Time Not Supplied
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at Upcoming Investor Conferences in August,2016-08-03 12:22:08 +0000,http://www.publicnow.com/view/108D5562455C265127EE88382599979FE914D0D9,"[at noodls] - CAMBRIDGE, Mass., Aug. 3, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016",2016-08-02 12:11:13 +0000,http://www.publicnow.com/view/856A34BBD57840554C9E2FEA37697AEF34C2E0C6,"[at noodls] - CAMBRIDGE, Mass., Aug. 2, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : June 28, 2016",2016-06-28 12:18:16 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-breached-its-50-day-moving-average-in-a-bearish-manner-bpmc-us-june-28-2016/,"Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : June 28, 2016"
BPMC,BPMC:UW,BBG008D08M37,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders",2016-06-24 20:31:47 +0000,http://biz.yahoo.com/e/160624/bpmc8-k.html,"BLUEPRINT MEDICINES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders"
BPMC,BPMC:UW,BBG008D08M37,"ETF’s with exposure to Blueprint Medicines Corp. : June 20, 2016",2016-06-20 18:07:54 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-blueprint-medicines-corp-june-20-2016/,"ETF’s with exposure to Blueprint Medicines Corp. : June 20, 2016"
BPMC,BPMC:UW,BBG008D08M37,"ETF’s with exposure to Blueprint Medicines Corp. : June 7, 2016",2016-06-07 21:29:34 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-blueprint-medicines-corp-june-7-2016/,"ETF’s with exposure to Blueprint Medicines Corp. : June 7, 2016"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016",2016-06-02 13:59:59 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-bpmc-us-earnings-analysis-q1-2016-by-the-numbers-june-2-2016/,"Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at Upcoming Investor Conferences in June,2016-06-01 20:25:09 +0000,http://www.publicnow.com/view/5C01F4BEE3FDA98F8AFABDD7D2E46209A7777AE7,"[at noodls] - CAMBRIDGE, Mass., June 1, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. – Value Analysis (NASDAQ:BPMC) : May 23, 2016",2016-05-23 21:49:19 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-value-analysis-nasdaqbpmc-may-23-2016/,"Blueprint Medicines Corp. – Value Analysis (NASDAQ:BPMC) : May 23, 2016"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Corp. breached its 50 day moving average in a Bullish Manner : BPMC-US : May 20, 2016",2016-05-20 12:06:54 +0000,http://www.capitalcube.com/blog/index.php/blueprint-medicines-corp-breached-its-50-day-moving-average-in-a-bullish-manner-bpmc-us-may-20-2016/,"Blueprint Medicines Corp. breached its 50 day moving average in a Bullish Manner : BPMC-US : May 20, 2016"
BPMC,BPMC:UW,BBG008D08M37,Edited Transcript of BPMC earnings conference call or presentation 10-May-16 12:00pm GMT,2016-05-11 18:44:02 +0000,http://finance.yahoo.com/news/edited-transcript-bpmc-earnings-conference-184402986.html,Edited Transcript of BPMC earnings conference call or presentation 10-May-16 12:00pm GMT
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Corp Earnings Call scheduled for 8:00 am ET today,2016-05-10 12:00:00 +0000,http://biz.yahoo.com/cc/4/152074.html,Blueprint Medicines Corp Earnings Call scheduled for 8:00 am ET today
BPMC,BPMC:UW,BBG008D08M37,8 Stocks Spiking on Big Volume,2016-05-10 11:30:00 +0000,http://www.thestreet.com/story/13564401/1/8-stocks-spiking-on-big-volume.html?puc=yahoo&cm_ven=YAHOO,8 Stocks Spiking on Big Volume
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines reports 1Q loss,2016-05-10 11:26:37 +0000,http://sg.finance.yahoo.com/news/blueprint-medicines-reports-1q-loss-112637328.html,Blueprint Medicines reports 1Q loss
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Reports First Quarter 2016 Financial Results,2016-05-10 11:18:08 +0000,http://www.publicnow.com/view/64CEA15E3158C5A4E13ACC41C17CB730779D0FC7,"[at noodls] - CAMBRIDGE, Mass., May 10, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016",2016-05-03 12:30:03 +0000,http://www.publicnow.com/view/C9A1C222BB1BE94976D13141C4874806F83B2BD8,"[at noodls] - CAMBRIDGE, Mass., May 3, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,New Strong Buy Stocks for April 25th,2016-04-25 15:59:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jYeZv6L8bnM/new-strong-buy-stocks-for-april-25th-cm610983,"Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) list today Align Technology, Inc.ALGNBazaarvoice IncBVBeacon Roofing Supply, Inc.BECNBenefitfocus IncBNFTBlueprint Medicines CorpBPMCView the entire Zacks Rank #1 List . Want the latest recommendations from Zacks Investment Research?"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines Appoints Lynn Seely, M.D. to Board of Directors",2016-04-15 12:19:56 +0000,http://www.publicnow.com/view/EB26C94D005D755BC7C2392D278E928585E1CCF0,"[at noodls] - CAMBRIDGE, Mass., April 15, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,New Strong Buy Stocks for April 13th,2016-04-13 16:07:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tWKzhLp9vE0/new-strong-buy-stocks-for-april-13th-cm605793,Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today AllianceBernstein Holding LPABAMC Networks IncAMCXBarracuda Networks IncCUDABazaarvoice IncBVBlueprint Medicines CorpBPMCView the entire Zacks Rank #1 List . Want the latest recommendations from Zacks Investment Research?
BPMC,BPMC:UW,BBG008D08M37,Will Blueprint Medicines (BPMC) Continue to Surge Higher?,2016-04-08 15:07:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d4rs_6Xj0IE/will-blueprint-medicines-bpmc-continue-to-surge-higher-cm603670,"As of late, it has definitely been a great time to be an investor Blueprint Medicines Corp BPMC . The stock has moved higher by 20.1% in the past month, while it is also above its 20 Day SMA"
BPMC,BPMC:UW,BBG008D08M37,New Strong Buy Stocks for April 7th,2016-04-07 17:05:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UJyhjnakwZA/new-strong-buy-stocks-for-april-7th-cm603172,"Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today American Superconductor CorporationAMSCBlackBerry LtdBBRYBlueprint Medicines CorpBPMCDarden Restaurants, IncDRIeGain CorpEGANView the entire Zacks Rank #1 List . Want the latest recommendations from Zacks Investment Research? Today,"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at 15th Annual Needham Healthcare Conference,2016-04-05 12:20:14 +0000,http://www.publicnow.com/view/901C516FE13C7EF3DD8A9C6132804E74152F9A34,"[at noodls] - CAMBRIDGE, Mass., April 5, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ..."
BPMC,BPMC:UW,BBG008D08M37,New Strong Buy Stocks for March 29th,2016-03-29 15:26:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lGvqeJ-xN4k/new-strong-buy-stocks-for-march-29th-cm598831,Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) list today Achaogen IncAKAOAtriCure Inc.ATRCBellatrix Exploration LtdBXEBlackrock Capital Investment CorpBKCCBlueprint Medicines CorpBPMCView the entire Zacks Rank #1 List . Want the latest recommendations from Zacks Investment Research?
BPMC,BPMC:UW,BBG008D08M37,"Bio-Techne Buys Zephyrus, Boosts Protein Platforms Division",2016-03-22 15:15:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PFzM2PxJmD0/bio-techne-buys-zephyrus-boosts-protein-platforms-division-cm596295,"Bio Techne CorpTECH recently acquired Zephyrus Biosciences, which will be integrated into the former's Protein Platforms Division. The acquisition will help Bio Techne provide researchers with tools that enable analysis of both homogeneous as well as heterogeneous sample population."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines reports 4Q loss,2016-03-11 13:14:46 +0000,http://sg.finance.yahoo.com/news/blueprint-medicines-reports-4q-loss-131244515.html,Blueprint Medicines reports 4Q loss
BPMC,BPMC:UW,BBG008D08M37,"Wednesday Sector Laggards: Biotechnology, Drugs",2016-02-03 20:14:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HWjTQc_H2TM/wednesday-sector-laggards-biotechnology-drugs-cm574411,"In trading on Wednesday, biotechnology shares were relative laggards, down on the day by about 2.4%. Helping drag down the group were shares of Fate Therapeutics ( FATE ), off about 12.2% and shares of Vascular Biogenics ( VBLT"
BPMC,BPMC:UW,BBG008D08M37,Chinese immunotherapy biotech BeiGene sets terms for $127 million IPO,2016-01-20 00:20:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/52pVvRoV5is/chinese-immunotherapy-biotech-beigene-sets-terms-for-127-million-ipo-cm567697,"BeiGene, a Chinese biotech developing immunotherapies based on kinase inhibitors, announced terms for its IPO on Tuesday. The Beijing, China based company plans to raise $126.5 million by offering 5.5 million ADSs at a price range of $22 to"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Strengthens Executive Leadership Team,2016-01-05 21:30:05 +0000,http://www.noodls.com/view/7AFA17727DBE4B2AD819EB273418E8CE2AC619F6,"[at noodls] - , /PRNewswire/ -- (NASDAQ: BPMC), a leader in discovering and developing highly selective investigational kinase medicines for patients with genomically defined diseases, today announced the appointment ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Added to NASDAQ Biotechnology Index,2015-12-17 22:06:14 +0000,http://www.noodls.com/view/0A0F35A6D8CD5B1E155B1C1096FEA83CC0BD289A,"[at noodls] - , /PRNewswire/ -- (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that it has been added to the ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present Preclinical Data at 2015 ASH Annual Meeting Demonstrating Anti-tumor Activity of BLU-285 in a Model of Acute Myeloid Leukemia,2015-11-12 13:56:11 +0000,http://www.noodls.com/view/70CE11B4E550C24E96183668837EE59760F17321,[at noodls] - Blueprint Medicines to Present Preclinical Data at 2015 ASH Annual Meeting Demonstrating Anti-tumor Activity of BLU-285 in a Model of Acute Myeloid Leukemia
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines reports 3Q loss,2015-11-09 21:59:39 +0000,http://sg.finance.yahoo.com/news/blueprint-medicines-reports-3q-loss-215939153.html,Blueprint Medicines reports 3Q loss
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Highlights Advances in Preclinical Discovery Efforts,2015-11-09 21:36:04 +0000,http://www.noodls.com/view/91811C282C4A9A3D913CD574C50369F3F91F3910,"[at noodls] - CAMBRIDGE, Mass. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Reports Third Quarter 2015 Financial Results,2015-11-09 21:16:20 +0000,http://www.noodls.com/view/18ECD42481BBCBB38DAE7859763D294C7F15E44E,"[at noodls] - CAMBRIDGE, Mass. , Nov. 9, 2015 /PRNewswire/ -- Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Receives FDA Orphan Drug Designation for Novel Drug Candidate for Treatment of Hepatocellular Carcinoma,2015-09-30 12:18:05 +0000,http://www.noodls.com/view/CE375EC7F8CEFD551117A78A8E22FB6DD7C79FFD,"[at noodls] - CAMBRIDGE, Mass., Sept. 30, 2015 /PRNewswire/ -- Blueprint Medicines (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its novel drug ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Slumps: BPMC Tanks 14.8% in Session,2015-09-23 14:44:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KTX_pIqH5G8/blueprint-medicines-slumps-bpmc-tanks-148-in-session-cm522855,"Blueprint Medicines Corporation ( BPMC ) saw a big move last session, as the company's shares fell nearly 15% on the day. The move came on pretty good volume too with far more shares changing hands than in a"
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis,2015-09-10 12:16:08 +0000,http://www.noodls.com/view/9459BC5672D812974E877D1FF132F0958FAA54C9,"[at noodls] - CAMBRIDGE, Mass., Sept. 10, 2015 /PRNewswire/ -- Blueprint Medicines (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) accepted the Company's Investigational New Drug (IND) ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present at the 22nd Annual NewsMakers in the Biotech Industry Conference,2015-09-03 12:35:16 +0000,http://www.noodls.com/view/E8E6D88B043C99E2BB1AED60E46B8696172315AA,"[at noodls] - CAMBRIDGE, Mass., Sept. 3, 2015 /PRNewswire/ -- Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today announced ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines to Present Preclinical Data on BLU-554 and on Novel Drug Target at International Liver Cancer Association 9th Annual Conference,2015-09-01 12:33:13 +0000,http://www.noodls.com/view/37A82CA8A87C1D08D487A17185297F3A7F5DF6B5,"[at noodls] - CAMBRIDGE, Mass., Sept. 1, 2015 /PRNewswire/ -- Blueprint Medicines (NASDAQ: BPMC) today announced that it will present preclinical data on its drug candidate BLU-554 in hepatocellular carcinoma (HCC), ..."
BPMC,BPMC:UW,BBG008D08M37,Blueprint Medicines (BPMC) Falls: Stock Goes Down 7.6% - Tale of the Tape,2015-06-22 14:34:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zY8i1ELsSY8/blueprint-medicines-bpmc-falls-stock-goes-down-76-tale-of-the-tape-cm489173,"Blueprint Medicines Corporation(BPMC) saw a big move in the last trading session, as the company's shares fell by nearly 8% on the day. The move came on pretty good volume too with far more shares changing hands than in"
BPMC,BPMC:UW,BBG008D08M37,"Health Care Sector Update for 06/12/2015: BPMC,TNXP,AVEO",2015-06-12 21:00:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dBi3HBJ8oCY/health-care-sector-update-for-06122015-bpmctnxpaveo-cm486671,"Top Health Care Stocks JNJ 0.90% PZE 0.73% MRK 0.79% ABT 1.77% AMGN 1.12% Health care stocks ended Friday trading mostly lower, with the NYSE Health Care Sector Index dropping 1.1% and shares of health care companies in the"
BPMC,BPMC:UW,BBG008D08M37,"Blueprint Medicines prices upsized IPO at $18, above the range",2015-04-29 23:15:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bM5XOaILGrk/blueprint-medicines-prices-upsized-ipo-at-18-above-the-range-cm471001,"Blueprint Medicines, a preclinical biotech developing kinase inhibitors for cancer and genetic diseases, raised $147 million by offering 8.1 million shares (upsized from 7.2 million shares) at $18, above the range of $15 to $17. Blueprint Medicines plans to"
BPMC,BPMC:UW,BBG008D08M37,Week ahead: 6 IPOs planned for the week of Apr 27,2015-04-28 17:21:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/szOEG7Ep9ho/week-ahead-6-ipos-planned-for-the-week-of-apr-27-cm470296,"Up to six companies could price their IPOs  this week . All are either LPs or health care companies (including three biotechs).Two LPs on deck, one offering power generating wood pelletsEnviva Partners LP ( EVA ) is backed by"
BPMC,BPMC:UW,BBG008D08M37,A blueprint for curing cancer: Blueprint Medicines files for a $100 million IPO,2015-03-25 21:06:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7iKFC7tPOS8/a-blueprint-for-curing-cancer-blueprint-medicines-files-for-a-100-million-ipo-cm457888,"Blueprint Medicines, a preclinical biotech developing kinase inhibitors for cancer and genetic diseases, filed on Monday with the SEC to raise up to $100 million in an initial public offering. The Cambridge, MA based company, which was founded in"
